Physician profile
Mark Ranck
NPI 1578710471
$2,390.83
in general payments reported to CMS, 2019-2025
25 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $172 · 2022: $105 · 2023: $327 · 2024: $1,307 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Food and Beverage | $801.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,050.00 | 2024 | Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $180.93 | 2019-2024 | |
| Boston Scientific Corporation | $142.08 | 2025 | Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $131.98 | 2024-2025 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $121.15 | 2023 | Reblozyl |
| Eisai INC. | $119.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $99.95 | 2020 | |
| Janssen Biotech, INC. | $59.23 | 2023-2024 | Imbruvica, Darzalex, Talvey |
| Pharmacyclics LLC, An Abbvie Company | $55.59 | 2019-2022 | |
| Genzyme Corporation | $51.23 | 2020-2022 | |
| Amgen INC. | $46.88 | 2023 | Lumakras, Vectibix, Xgeva |
| Regeneron Healthcare Solutions, INC. | $46.38 | 2023-2024 | Libtayo |
| Myovant Sciences INC. | $38.24 | 2022 | |
| Taiho Oncology, INC. | $33.68 | 2024 | |
| Tersera Therapeutics LLC | $25.80 | 2023 | Zoladex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $25.69 | 2025 | Eclipse Treatment Planning System For External Beam Radiation Therapy, Truebeam |
| Lilly USA, LLC | $24.55 | 2019-2020 | |
| Novocure INC. | $22.68 | 2019 | |
| Fortovia Therapeutics, INC. | $21.14 | 2019 | |
| Incyte Corporation | $20.38 | 2024 | Jakafi |
| Sobi, INC | $17.75 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.10 | 2019 | |
| Dova Pharmaceuticals | $15.79 | 2019 | |
| Elekta, INC. | $12.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ranck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.